IMAB - שווי פעילות I-Mab

I-Mab (IMAB) operations are complicated by geopolitics, the BioSecure Act, and clinical trial uncertainty, as confirmed by this price chart on GURU.Markets, where the Enterprise Value is . The company generates revenue through licenses and alliances with pharma behemoths, developing antibodies against tumors. The business relies on the cross-border exchange of molecules within R&D alliances while facing stringent regulation from the US and China.

For I-Mab (IMAB), which is currently undergoing an asset divestiture and focusing on high-risk oncology developments, business valuation dynamics are critically important. By analyzing the aggregate market value, an investor can determine the actual buyout price of the company—calculated as the sum of market capitalization and debt minus cash—which allows for an objective assessment of the enterprise's scale amid the high binary nature of the biotechnology sector.